港股创新药概念股震荡走强，相关ETF涨近3%

Group 1 - The core viewpoint is that Hong Kong's innovative pharmaceutical stocks are experiencing a strong upward trend, with notable increases in companies such as Kangfang Biotech (over 6%), Innovent Biologics (over 5%), and Zai Lab (over 4%) [1] - Several Hong Kong innovative pharmaceutical-related ETFs have also risen nearly 3% due to market influences [1] - The analysis indicates that the overseas easing cycle typically benefits biotech assets, with the Nasdaq Biotechnology Index rising by 13% since the interest rate cut on September 18, 2025, suggesting an improved financing environment that may enhance the operational vitality of biotech companies [2] Group 2 - Recent positive developments in China's biotechnology sector include multiple innovative pharmaceutical companies having 35 studies selected for oral presentations at the ESMO 2025 conference, setting a new record [3] - Significant benchmark business development collaborations are emerging, such as the partnership between Innovent Biologics and Takeda, which has a total scale of up to $11.4 billion, reflecting global market recognition of the value of Chinese innovative drugs [3]